Latest Channelopathy Stories
EPIX Pharmaceuticals, Inc.
Kamada, a biopharmaceutical company, has reported positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin delivered via an investigational eFlow Nebulizer System, in the treatment of cystic fibrosis.
REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it is seeking a strategic partner to assist in the development of RGN-457 for the treatment of cystic fibrosis (CF).
Scientists hope that a new development, which allows them to create pigs that develop cystic fibrosis in the same way the people do, will give them new insight into fighting the disease.
WARRINGTON, Pa., Sept. 3, 2008 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) announces that its proprietary, aerosolized KL-4 surfactant has been selected for a Phase 2a clinical trial in patients with Cystic Fibrosis (CF).
LINCOLN, R.I., Sept. 3 /PRNewswire/ -- Neurotech Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of sight-saving therapeutics for chronic retinal diseases, announced today that the U.S.
What was your first experience of cystic fibrosis? I have two grandsons, now in their twenties, who were diagnosed at birth. It's a shock when you hear that news and you don't really know anything about the disease.
Kamada has completed a Phase II study with aerosolized alpha-1 antitrypsin, delivered via an optimized eFlow platform nebulizer from PARI Pharma, in cystic fibrosis.
Research and Markets (http://www.researchandmarkets.com/research/8e04b4/cystic_fibrosis_w) has announced the addition of Decision Resources, Inc.'s new report "Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies?" to their offering.
WALTHAM, Mass., July 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in 2007, the United States market for the treatment of pulmonary symptoms of cystic fibrosis reached $397 million, reflecting primarily sales of Genentech/Roche's Pulmozyme and Novartis's antibiotic Tobi.
Cystic fibrosis, also called mucoviscidosis, is an autosomal recessive genetic disorder of the viscous secretions in the body. In turn, it effects the lungs, pancreas, liver, and intestines, as well as all other exocrine glands in the body. The most common genetic mutation that causes CF is a deletion of three nucleotides that results in a loss of phenylalanine, an amino acid at the 508th position on the protein. It should be noted, however, that there are over a thousand other mutations that...
- A woman chauffeur.
- A woman who operates an automobile.